171 related articles for article (PubMed ID: 37551745)
21. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
[TBL] [Abstract][Full Text] [Related]
22. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
[TBL] [Abstract][Full Text] [Related]
23. mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Garros-Regulez L; Aldaz P; Arrizabalaga O; Moncho-Amor V; Carrasco-Garcia E; Manterola L; Moreno-Cugnon L; Barrena C; Villanua J; Ruiz I; Pollard S; Lovell-Badge R; Sampron N; Garcia I; Matheu A
Expert Opin Ther Targets; 2016; 20(4):393-405. PubMed ID: 26878385
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and Characterization of a Series of Temozolomide Esters and Its Anti-glioma Study.
Yu Y; Wang L; Han J; Wang A; Chu L; Xi X; Kan R; Sha C; Sun K
J Pharm Sci; 2021 Oct; 110(10):3431-3438. PubMed ID: 34147518
[TBL] [Abstract][Full Text] [Related]
25. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA
Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956
[TBL] [Abstract][Full Text] [Related]
26. miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway.
Li H; Chen L; Li JJ; Zhou Q; Huang A; Liu WW; Wang K; Gao L; Qi ST; Lu YT
J Hematol Oncol; 2018 May; 11(1):70. PubMed ID: 29843746
[TBL] [Abstract][Full Text] [Related]
27. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
28. Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide.
Alafate W; Wang M; Zuo J; Wu W; Sun L; Liu C; Xie W; Wang J
Pathol Res Pract; 2019 Nov; 215(11):152617. PubMed ID: 31563286
[TBL] [Abstract][Full Text] [Related]
29. Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis.
Qu S; Qi S; Zhang H; Li Z; Wang K; Zhu T; Ye R; Zhang W; Huang G; Yi GZ
J Exp Clin Cancer Res; 2023 Oct; 42(1):285. PubMed ID: 37891669
[TBL] [Abstract][Full Text] [Related]
30. Hsa_circ_0043949 reinforces temozolomide resistance via upregulating oncogene ITGA1 axis in glioblastoma.
Li X; Wang N; Leng H; Yuan H; Xu L
Metab Brain Dis; 2022 Dec; 37(8):2979-2993. PubMed ID: 36301458
[TBL] [Abstract][Full Text] [Related]
31. Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7.
Wang J; Li T; Wang B
Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34278448
[TBL] [Abstract][Full Text] [Related]
32. Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2.
Chen L; Li Z; Hu S; Deng Q; Hao P; Guo S
Cancer Chemother Pharmacol; 2022 Feb; 89(2):217-229. PubMed ID: 35039898
[TBL] [Abstract][Full Text] [Related]
33. Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM.
Juric V; Düssmann H; Lamfers MLM; Prehn JHM; Rehm M; Murphy BM
Cells; 2021 May; 10(5):. PubMed ID: 34066147
[TBL] [Abstract][Full Text] [Related]
34. NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition.
Tsai CY; Ko HJ; Chiou SJ; Lai YL; Hou CC; Javaria T; Huang ZY; Cheng TS; Hsu TI; Chuang JY; Kwan AL; Chuang TH; Huang CF; Loh JK; Hong YR
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072831
[TBL] [Abstract][Full Text] [Related]
35. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
36. TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Morelli MB; Nabissi M; Amantini C; Maggi F; Ricci-Vitiani L; Pallini R; Santoni G
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499683
[TBL] [Abstract][Full Text] [Related]
37. Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells.
Noh H; Zhao Q; Yan J; Kong LY; Gabrusiewicz K; Hong S; Xia X; Heimberger AB; Li S
Cancer Lett; 2018 Oct; 433():176-185. PubMed ID: 29991446
[TBL] [Abstract][Full Text] [Related]
38. PTRF/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma.
Yang E; Wang L; Jin W; Liu X; Wang Q; Wu Y; Tan Y; Wang Y; Cui X; Zhao J; Tong F; Hong B; Xiao M; Liu X; Fang C; Kang C
Theranostics; 2022; 12(9):4330-4347. PubMed ID: 35673568
[No Abstract] [Full Text] [Related]
39. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
[TBL] [Abstract][Full Text] [Related]
40. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
